Skip to main content
. 2010 Jul 26;54(10):4440–4445. doi: 10.1128/AAC.01749-09

TABLE 3.

Safety summary

Event Incidence, n (%) (n = 18 volunteers/treatment)
A (DRV/r) B (RFB) C (DRV/r + RFB)
Any adverse event 5 (28) 8 (44) 15 (83)
≥1 serious adverse event 0 2 (11) 2 (11)
≥1 grade 3 or 4 adverse event 0 2 (11) 3 (17)
≥1 adverse event leading to permanent discontinuation of trial medication 0 2 (11) 5 (28)
Laboratory abnormalities
    ≥1 worst grade 3 or 4 laboratory abnormality 1 (6) 9 (53) 3 (17)
    ≥1 laboratory abnormality leading to permanent discontinuation 0 2 (11) 0